Skip to main content

Table 2 Patient characteristics

From: Hypersensitivity to oxaliplatin: clinical features and risk factors

Patient characteristics (n = 191)

Mean (range)

n (%)

Age (years)

62.4 (23–84)

 

Sex, male

 

78 (41)

Atopic diseases

 

32 (17)

Diagnosis

  

Colon

 

86 (45)

Stomach

 

10 (5)

Ovary

 

35 (18)

Pancreas

 

9 (5)

Peritoneum

 

8 (4)

Rectum

 

25 (13)

Other1

 

18 (10)

Prior platinum exposure, yes

 

45 (24)

Treament regimen

  

FOLFOX4 (oxaliplatin, 5-fluorouracil and leucovorin)

 

101 (53)

FOLFOX4-bevacizumab

 

10 (5)

FOLFOX4-cetuximab

 

4 (2)

GEMOX (oxaliplatin and gemcitabine)

 

47 (25)

Oxaliplatin alone

 

5 (3)

TOMOX(oxaliplatin and raltitrexed)

 

12 (6)

Other2

 

12 (6)

Total infusion courses

6.4 (1–18)

 

Oxaliplatin dose (mg/m2)

85.3 (42–160)

 
  1. 1Includes: appendix (2), gallbladder (4), liver (2), mouth (1), oesophagus (2), endometrium (1) and unknown primary (6).
  2. 2Includes: 2 ELOGEM (combination of oxaliplatin and gemcitabine), 2 EOX (combination of oxaliplatin, epirubicin and capecitabine), 2 FOLFIRINOX (combination of oxaliplatin, irinotecan, 5-fluorouracil and leucovorin), 1 FOLFOX6 (combination of oxaliplatin, 5-fluorouracil and leucovorin), 2 FOLFOX7 (combination of oxaliplatin, 5-fluorouracil and leucovorin), 1 patient treated with oxaliplatin and epirubicine, 1 oxaliplatin with cetuximab and 1 XELOX (combination of oxaliplatin and capecitabine).